Embla Medical hf (EMBLA) fair value: what the stock is really worth
We calculate from audited financials what Embla Medical hf is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Embla Medical hf for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range kr 25.16 – kr 49.20 · fair‑value band kr 19.73 – kr 37.32 · the kr 27.15 price screens below the kr 29.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care.
Show more
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides osteoarthritis solutions that are designed to reduce pain and improve mobility for people living with osteoarthritis; and injury solutions for people recovering from fractures, ligament injuries, or need post-operative treatment. This segment also offers Unloader One, a range knee braces that relieve pain from knee osteoarthritis; and Unloader Hip, which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip. The Patient Care segment provides prosthetics for people with lower and upper limb loss or limb difference; and orthotics for neurological, gait, and musculoskeletal conditions. The company serves orthopedic and prosthetic clinics, hospitals, and surgery centers. It sells its products through its direct sales networks and distributors. The company was formerly known as Össur hf. and changed its name to Embla Medical hf. in April 2024. Embla Medical hf. was incorporated in 1971 and is headquartered in Reykjavik, Iceland. Embla Medical hf. is a subsidiary of William Demant Invest A/S.
Stock analysis
Embla Medical hf (EMBLA) currently trades at kr 27.15, while our model-based Fair Value estimate is kr 29.87, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 4.72 per share, and 0 of the 26 models we run sit above the kr 27.15 price.
Bear case: the Growth Earnings group reads lowest at kr 3.34, and 26 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: kr 19.73 (bear) to kr 37.32 (bull), the price of kr 27.15 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Embla Medical hf reported revenue of $964M in FY2025 versus $719M in FY2021, a compound +7.6%/yr. Reported net income was $86.5M in FY2025, compounding +7.8%/yr from FY2021.
Key figures
Market cap 11.6B DKK (≈ $1.8B) · P/E ratio 21.0 · P/S ratio 1.89 · EPS (TTM) kr 1.29 · Dividend yield 0.1% · Net margin 9.0% · Return on equity 10.1% · Return on assets (EBIT) 6.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 28% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 0% fair-value upside, at 10%, EMBLA screens cheaper than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (kr 0.3500 to kr 6.33). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear kr 19.73Fair Value kr 29.87Bull kr 37.32
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (kr 0.9365 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.78/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.9%
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+6.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.0%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6% vs 6%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 13%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+40.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.6%
Yearly sales growth analysts expect, extended to five years.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 356 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside−87% · Bottom 25%
Profitability
Return on equity (TTM)10% · Above median
Return on assets5% · Above median
Net margin (TTM)9% · Above median
Operating margin (TTM)10% · Above median
Growth and dividend
Revenue growth15% · Above median
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.33× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Embla Medical hf Fair Value". https://www.fairvalue-calculator.com/stock/EMBLA
Frequently asked questions
Is Embla Medical hf (EMBLA) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of kr 29.87 versus a price of kr 27.15, about +10% upside (undervalued).
What is the fair value of EMBLA?
Our model-based fair value for Embla Medical hf is kr 29.87 (as of Sep 13, 2026), built from audited fundamentals. The current price: kr 27.15.
What is the quality score of EMBLA?
Embla Medical hf has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Embla Medical hf (EMBLA)?
Our model-based price target is the fair value of kr 29.87 (as of Sep 13, 2026) from 26 valuation models. Cautious scenario kr 19.73, optimistic scenario kr 37.32. It is a calculation from audited fundamentals, not an analyst target.
What is the Embla Medical hf stock forecast for 2026?
Our models put fair value at kr 29.87, about +10% upside versus a price of kr 27.15 (undervalued). Cautious scenario kr 19.73, optimistic scenario kr 37.32. The calculation is refreshed regularly with new filings.
What is the revenue of Embla Medical hf (EMBLA)?
Embla Medical hf reported trailing-twelve-month revenue of about 958M DKK (latest available figure, as of Sep 13, 2026).
Does Embla Medical hf pay a dividend?
Embla Medical hf currently shows a dividend yield of about 0.08% relative to its recent price (as of Sep 13, 2026).
What growth is priced into Embla Medical hf (EMBLA)?
For today's price to be fair in a discounted-cash-flow model, Embla Medical hf would have to grow free cash flow by +40.7 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.9 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of EMBLA use?
Our models discount Embla Medical hf at 9.6 %: a base by market capitalisation (small), damped by beta 0.45, country premium for Denmark. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Embla Medical hf that is +40.7 % per year a year over ten years, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has Embla Medical hf (EMBLA) delivered so far?
Over the past 5 years revenue at Embla Medical hf grew +8.9 % a year. The price currently implies +40.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Embla Medical hf (EMBLA) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Embla Medical hf (+40.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Embla Medical hf (EMBLA)?
The free-cash-flow yield on the price is 1.03 %: that much free cash flow Embla Medical hf produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Embla Medical hf (EMBLA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Embla Medical hf it is kr 29.87 per share (as of Sep 13, 2026), against a price of kr 27.15. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Embla Medical hf stock overvalued or undervalued in 2026?
As of Sep 13, 2026, EMBLA trades below its calculated fair value: price kr 27.15, fair value kr 29.87, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EMBLA?
No. The price is what the market pays today (kr 27.15); the fair value is what the company's own numbers justify (kr 29.87). For Embla Medical hf the two are kr 2.72 per share apart. That gap is exactly why we show both numbers side by side.
How much is Embla Medical hf worth?
The market values Embla Medical hf at about 11.6B DKK (market capitalisation, as of Sep 13, 2026). Per share that is kr 27.15; our models calculate a fair value of kr 29.87 per share.
What do the bullish and bearish scenarios say about EMBLA?
Our models span a range for Embla Medical hf: cautious scenario kr 19.73, base kr 29.87, optimistic kr 37.32 per share (as of Sep 13, 2026, price kr 27.15). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EMBLA?
Embla Medical hf trades at a price-to-earnings ratio of 21.0 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 29.87 is built from several models across several years. Other multiples: P/B 2.0, P/S 1.8, EV/EBITDA 12.9.
How solid is the balance sheet of Embla Medical hf (EMBLA)?
Balance-sheet figures for Embla Medical hf (as of Sep 13, 2026): return on equity 10.1%, debt of 0.33 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is EMBLA from its 52-week high?
Embla Medical hf trades at kr 27.15, about 28% below its 52-week high of kr 37.90 and 9% above the low of kr 25.00 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of kr 29.87 is for.
Which stocks are comparable to Embla Medical hf?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Embla Medical hf stock attractive at the current price?
The data as of Sep 13, 2026: price kr 27.15, calculated fair value kr 29.87 (+10%), Quality Score 60/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EMBLA calculated?
We run Embla Medical hf through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 29.87, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Embla Medical hf currently trades 10 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Embla Medical hf right now?
A fairly wide model range (kr 19.73 to kr 37.32) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Embla Medical hf (EMBLA) come from?
Earnings per share at Embla Medical hf grew +3.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.9 %, EBIT margin −2.3 %, tax rate +0.2 %, residual (interest, one-offs) −1.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Embla Medical hf
How large is the market capitalisation of Embla Medical hf (EMBLA)?
The market capitalisation of Embla Medical hf is 11.6B DKK (≈ $1.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Embla Medical hf (EMBLA)?
The price-to-sales ratio of Embla Medical hf is 1.89 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Embla Medical hf (EMBLA)?
Earnings per share at Embla Medical hf are kr 1.29 (price ÷ EPS = P/E 21.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Embla Medical hf (EMBLA)?
The dividend yield of Embla Medical hf is 0.1% (payout 1.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Embla Medical hf (EMBLA)?
The net margin of Embla Medical hf is 9.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Embla Medical hf (EMBLA)?
The return on equity (ROE) of Embla Medical hf is 10.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Embla Medical hf (EMBLA)?
On an EBIT basis the return on assets of Embla Medical hf is 6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Embla Medical hf (EMBLA)?
The operating margin of Embla Medical hf is 9.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Embla Medical hf (EMBLA)?
Revenue at Embla Medical hf is growing +14.6% versus a year earlier (3y avg +10.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Embla Medical hf (EMBLA)?
Earnings per share at Embla Medical hf are growing +21.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Embla Medical hf (EMBLA) carry?
The net debt of Embla Medical hf is 591M DKK (fiscal year 2025, ≈ 5.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Embla Medical hf in the live analysis
One click puts Embla Medical hf on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
